Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
ORIC Pharmaceuticals Inc. (ORIC) Announces $125 Million Private Placement at $6.50/sh
-
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
-
Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer
-
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Oric Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G ACUREN CORP Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Mar 31
-
Mythic Therapeutics to Present Updated Dose Escalation Data from Phase 1 KisMET-01 Study on MYTX-011 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Canopy Secures $70 Million Series C to Unclunk Accounting Firms with AI
-
DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa
-
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Associati
-
Form SCHEDULE 13G REGAL REXNORD CORP Filed by: VIKING GLOBAL INVESTORS LP
-
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
-
Revive Environmental and Battelle Partner on DoD-Funded Project to Eliminate Toxic “Forever Chemicals”
-
Pearl Health Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance
-
Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors
-
North Carolina Selects Revive Environmental for Statewide PFAS Destruction in AFFF Take-Back Program
-
Revive Environmental Welcomes Douglas Hendry as Chief Technology Officer
-
Patina Launches New Service, Patina Total Health (TM), to Make Personalized, Age-Friendly Care Accessible to Medicare Advantage Members
-
Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G Sionna Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A Longboard Pharmaceutical Filed by: VIKING GLOBAL INVESTORS LP
-
Form SCHEDULE 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Hedge fund Viking buys Boeing shares, adds more JPMorgan, filing shows
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31
-
TruBridge (TBRG) Announces Two Directors to Join Its Board as a Part of Cooperation Agreements With Pinetree Capital and Ocho Investments
-
TruBridge Announces Two Directors to Join Its Board as a Part of Cooperation Agreements With Pinetree Capital and Ocho Investments
-
Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 144 BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
DeepScribe and Pearl Health Announce Partnership to Bring Ambient AI Documentation to Value-based Care Providers
-
Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025
-
Virginia Care Partners, an HCA Virginia Affiliate, and Pearl Health Establish Partnership to Expand Access to Value-Based Care
-
Valsoft Corporation Secures $150M to Further Accelerate Growth in Vertical Market Software Sector
-
GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases
-
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
-
ID.me Announces Closing of Secondary Tender
-
Form SC 13G/A Tourmaline Bio, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Edgewise Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Viking Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Sep 30
-
Tesla, financials and other 'Trump trades' drew funds in Q3, filings show
-
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio

